EULAR® 2024 Insights: Long-Term Improvements in Serum Uric Acid Levels, Gout Symptoms, and Safety Up to 12-Months With SEL-212 in Gout Refractory to Conventional Therapy: Results From the DISSOLVE I Phase 3, Double-Blind, Placebo-Controlled Clinical Trial

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EULAR® 2024 Insights: Long-Term Improvements in Serum Uric Acid Levels, Gout Symptoms, and Safety Up to 12-Months With SEL-212 in Gout Refractory to Conventional Therapy: Results From the DISSOLVE I Phase 3, Double-Blind, Placebo-Controlled Clinical Trial

By EULAR® 2024 Insights FEATURING Alan Kivitz

0 views

June 21, 2024

Comments 0

USSONAR Rheumatology Ultrasound Case Series Featuring Dr. Phil Chu